Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escherichia phage NTNC80A
- Development stage
- Preclinical
- Lead developer
- Post Graduate Institute of Medical Education and Research
01
Overview
NTNC80A (Escherichia phage NTNC80A) is a lytic bacteriophage belonging to the class Caudoviricetes (specifically the species *Rodentiumvirus NTNC80A*) that targets multidrug-resistant (MDR) uropathogenic *Escherichia coli* (UPEC). Developed by the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh, India, NTNC80A is being investigated for the treatment of refractory urinary tract infections (UTIs). Preclinical studies demonstrate a strong phage-antibiotic synergy (PAS) when NTNC80A is administered simultaneously with sub-inhibitory doses of ciprofloxacin. This synergy is driven by ciprofloxacin-induced bacterial cell filamentation, which disrupts the peptidoglycan layer and enhances bacterial susceptibility to phage-mediated lysis, leading to accelerated bacterial clearance and reduced emergence of resistance.
- Other names
- bacteriophage NTNC80Aphage NTNC80A
Beyond the preview
Go deeper on Escherichia phage NTNC80A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Escherichia phage NTNC80A.